马拉维通过综合运动和后续常规免疫接种引入伤寒结合疫苗的成本

IF 2.7 Q3 IMMUNOLOGY Vaccine: X Pub Date : 2024-11-13 DOI:10.1016/j.jvacx.2024.100583
Frédéric Debellut , George Bello , Mike Chisema , Rouden Mkisi , Moses Kamzati , Clint Pecenka , Emmanuel Mugisha
{"title":"马拉维通过综合运动和后续常规免疫接种引入伤寒结合疫苗的成本","authors":"Frédéric Debellut ,&nbsp;George Bello ,&nbsp;Mike Chisema ,&nbsp;Rouden Mkisi ,&nbsp;Moses Kamzati ,&nbsp;Clint Pecenka ,&nbsp;Emmanuel Mugisha","doi":"10.1016/j.jvacx.2024.100583","DOIUrl":null,"url":null,"abstract":"<div><div>Malawi introduced typhoid conjugate vaccine (TCV) in 2023 through an integrated campaign delivering TCV alongside other vaccines and interventions (measles rubella vaccine (MRV), bivalent oral polio vaccine (OPV), and vitamin A Supplementation). The campaign sought to reach all children 9 months to younger than 14 years, representing more than 9 million individuals, and about half the country’s population. Following the campaign, TCV was incorporated into the routine immunization program for 9-month-old infants. We conducted a micro-costing study at 50 randomly selected health facilities, 10 districts, and at national level to retrospectively assess the financial and economic cost of the integrated campaign, as well as prospectively estimate the cost of delivering TCV in the routine immunization system. The financial and economic costs per dose for all interventions delivered in the campaign were $0.49 ($0.42;$0.57) and $0.84 ($0.67;$1.02), respectively. The main activities and cost types varied; human resources represented the main resource at health facility level, and per diem at district and national levels. The financial and economic cost to routinely deliver a dose of TCV were $0.44 ($0.17;$0.87), and $2.37 ($1.39;$3.53), respectively, with human resources as the main resource used by the routine program at all levels.</div><div>The cost per dose delivered in the integrated campaign in Malawi was comparable with other integrated campaigns and was lower than the reported cost to deliver TCV in single antigen campaigns in India and Zimbabwe. Integrated campaigns may represent an opportunity to introduce new vaccines such as TCV to lower the cost per dose delivered. Attention should be given to challenges coming with integration, such as the burden for healthcare workers.</div><div>Evidence produced by this study can be used in Malawi to inform financial sustainability of the TCV program and should inform decisions and strategies for implementation by other countries.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"21 ","pages":"Article 100583"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi\",\"authors\":\"Frédéric Debellut ,&nbsp;George Bello ,&nbsp;Mike Chisema ,&nbsp;Rouden Mkisi ,&nbsp;Moses Kamzati ,&nbsp;Clint Pecenka ,&nbsp;Emmanuel Mugisha\",\"doi\":\"10.1016/j.jvacx.2024.100583\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Malawi introduced typhoid conjugate vaccine (TCV) in 2023 through an integrated campaign delivering TCV alongside other vaccines and interventions (measles rubella vaccine (MRV), bivalent oral polio vaccine (OPV), and vitamin A Supplementation). The campaign sought to reach all children 9 months to younger than 14 years, representing more than 9 million individuals, and about half the country’s population. Following the campaign, TCV was incorporated into the routine immunization program for 9-month-old infants. We conducted a micro-costing study at 50 randomly selected health facilities, 10 districts, and at national level to retrospectively assess the financial and economic cost of the integrated campaign, as well as prospectively estimate the cost of delivering TCV in the routine immunization system. The financial and economic costs per dose for all interventions delivered in the campaign were $0.49 ($0.42;$0.57) and $0.84 ($0.67;$1.02), respectively. The main activities and cost types varied; human resources represented the main resource at health facility level, and per diem at district and national levels. The financial and economic cost to routinely deliver a dose of TCV were $0.44 ($0.17;$0.87), and $2.37 ($1.39;$3.53), respectively, with human resources as the main resource used by the routine program at all levels.</div><div>The cost per dose delivered in the integrated campaign in Malawi was comparable with other integrated campaigns and was lower than the reported cost to deliver TCV in single antigen campaigns in India and Zimbabwe. Integrated campaigns may represent an opportunity to introduce new vaccines such as TCV to lower the cost per dose delivered. Attention should be given to challenges coming with integration, such as the burden for healthcare workers.</div><div>Evidence produced by this study can be used in Malawi to inform financial sustainability of the TCV program and should inform decisions and strategies for implementation by other countries.</div></div>\",\"PeriodicalId\":43021,\"journal\":{\"name\":\"Vaccine: X\",\"volume\":\"21 \",\"pages\":\"Article 100583\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590136224001566\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

马拉维于 2023 年引入了伤寒结合疫苗 (TCV),通过一项综合运动,在接种伤寒结合疫苗的同时接种其他疫苗和干预措施(麻疹风疹疫苗 (MRV)、二价口服脊髓灰质炎疫苗 (OPV) 和维生素 A 补充剂)。该运动旨在覆盖所有 9 个月至 14 岁以下的儿童,人数超过 900 万,约占全国人口的一半。活动结束后,TCV 被纳入了 9 个月大婴儿的常规免疫计划。我们在随机抽取的 50 家医疗机构、10 个地区和全国范围内开展了一项微观成本核算研究,以回顾性评估综合运动的财务和经济成本,并对常规免疫系统中提供 TCV 的成本进行前瞻性估算。活动中所有干预措施的每剂财务和经济成本分别为 0.49 美元(0.42 美元;0.57 美元)和 0.84 美元(0.67 美元;1.02 美元)。主要活动和成本类型各不相同;在医疗机构层面,人力资源是主要资源,在地区和国家层面,每日津贴是主要资源。马拉维综合运动中每剂 TCV 的成本与其他综合运动相当,低于印度和津巴布韦报告的单抗原运动中每剂 TCV 的成本。综合疫苗接种活动可能是引入 TCV 等新疫苗以降低每剂疫苗接种成本的一个机会。这项研究提供的证据可用于马拉维,为 TCV 计划的财务可持续性提供信息,并为其他国家的实施决策和战略提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi
Malawi introduced typhoid conjugate vaccine (TCV) in 2023 through an integrated campaign delivering TCV alongside other vaccines and interventions (measles rubella vaccine (MRV), bivalent oral polio vaccine (OPV), and vitamin A Supplementation). The campaign sought to reach all children 9 months to younger than 14 years, representing more than 9 million individuals, and about half the country’s population. Following the campaign, TCV was incorporated into the routine immunization program for 9-month-old infants. We conducted a micro-costing study at 50 randomly selected health facilities, 10 districts, and at national level to retrospectively assess the financial and economic cost of the integrated campaign, as well as prospectively estimate the cost of delivering TCV in the routine immunization system. The financial and economic costs per dose for all interventions delivered in the campaign were $0.49 ($0.42;$0.57) and $0.84 ($0.67;$1.02), respectively. The main activities and cost types varied; human resources represented the main resource at health facility level, and per diem at district and national levels. The financial and economic cost to routinely deliver a dose of TCV were $0.44 ($0.17;$0.87), and $2.37 ($1.39;$3.53), respectively, with human resources as the main resource used by the routine program at all levels.
The cost per dose delivered in the integrated campaign in Malawi was comparable with other integrated campaigns and was lower than the reported cost to deliver TCV in single antigen campaigns in India and Zimbabwe. Integrated campaigns may represent an opportunity to introduce new vaccines such as TCV to lower the cost per dose delivered. Attention should be given to challenges coming with integration, such as the burden for healthcare workers.
Evidence produced by this study can be used in Malawi to inform financial sustainability of the TCV program and should inform decisions and strategies for implementation by other countries.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine: X
Vaccine: X Multiple-
CiteScore
2.80
自引率
2.60%
发文量
102
审稿时长
13 weeks
期刊最新文献
Immunogenicities of vaccines including the immunoglobulin M-degrading enzyme of Streptococcus suis, rIdeSsuis, and protective efficacy against serotype 14 in piglets The importance of quality of health campaign information for outcome evaluation. A case study from Guinea-Bissau and Bangladesh Mumps outbreak in Zimbabwe: The case for universal MMR vaccination in Africa The clinical and economic value of enhanced influenza vaccines for the elderly in Argentina Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1